Sugammadex

Sugammadex is a modified gamma-cyclodextrin and the first selective relaxant binding agent, used to reverse neuromuscular blockade induced by the aminosteroidal nondepolarizing neuromuscular blocking agents rocuronium and vecuronium during general anesthesia. It works by encapsulating these steroidal neuromuscular blocking drugs in plasma, forming tight 1:1 water-soluble complexes that prevent their action at the neuromuscular junction. This creates a concentration gradient that draws the muscle relaxant away from its site of action, rapidly reversing paralysis. Sugammadex does not inhibit acetylcholinesterase and therefore avoids cholinergic side effects associated with traditional reversal agents like neostigmine. It is administered intravenously at the end of surgery to restore muscle function. Developed by Organon and manufactured by Merck Sharp and Dohme.

Brand names

Bridion

Other names

sugammadex sodiummodified gamma-cyclodextrin